1. Updated guidance regarding the risk of allergic reactions to COVID-19 vaccines and recommended evaluation and management: A GRADE assessment and international consensus approach.
- Author
-
Greenhawt, Matthew, Dribin, Timothy, Abrams, Elissa, Shaker, Marcus, Chu, Derek, Golden, David, Akin, Cem, Anagnostou, Akterini, ALMuhizi, Faisal, Alqurashi, Waleed, Arkwright, Peter, Baldwin, James, Banerji, Aleena, Bégin, Philippe, Ben-Shoshan, Moshe, Bernstein, Jonathan, Bingemann, Theresa, Bindslev-Jensen, Carsten, Blumenthal, Kim, Byrne, Aideen, Cahill, Julia, Cameron, Scott, Campbell, Dianne, Campbell, Ronna, Cavender, Michael, Chan, Edmond, Chinthrajah, Sharon, Comberiati, Pasquale, Eastman, Jacqueline, Ellis, Anne, Fleischer, David, Fox, Adam, Frischmeyer-Guerrerio, Pamela, Gagnon, Remi, Garvey, Lene, Grayson, Mitchell, Isabwe, Ghislaine, Hartog, Nicholas, Hendron, David, Horner, Caroline, Hourihane, Johnathan, Iglesia, Edward, Kan, Manstein, Kaplan, Blanka, Katelaris, Constance, Kim, Harold, Kelso, John, Khan, David, Lang, David, Ledford, Dennis, Levin, Michael, Lieberman, Jay, Loh, Richard, Mack, Douglas, Mazer, Bruce, Mody, Ketan, Mosnaim, Gisele, Munblit, Daniel, Mustafa, S, Nanda, Anil, Nathan, Richard, Oppenheimer, John, Otani, Iris, Park, Miguel, Pawankar, Ruby, Perrett, Kirsten, Peter, Jonny, Phillips, Elizabeth, Picard, Matthieu, Pitlick, Mitchell, Ramsey, Allison, Rasmussen, Trine, Rathkopf, Melinda, Reddy, Hari, Robertson, Kara, Rodriguez Del Rio, Pablo, Sample, Stephen, Sheshadri, Ajay, Sheik, Javed, Sindher, Sayantani, Spergel, Jonathan, Stone, Cosby, Stukus, David, Tang, Mimi, Tracy, James, Turner, Paul, Vander Leek, Timothy, Wallace, Dana, Wang, Julie, Wasserman, Susan, Weldon, David, Wolfson, Anna, Worm, Margitta, and Yacoub, Mona-Rita
- Subjects
COVID-19 ,SARS-CoV-2 ,allergic reactions ,anaphylaxis ,mRNA COVID-19 vaccine ,polyethylene glycol ,polysorbate 80 ,repeat allergic reactions ,skin testing ,vaccination ,Humans ,COVID-19 Vaccines ,GRADE Approach ,Consensus ,Vaccine Excipients ,COVID-19 ,Hypersensitivity ,Immediate ,Anaphylaxis ,Excipients - Abstract
This guidance updates 2021 GRADE (Grading of Recommendations Assessment, Development and Evaluation) recommendations regarding immediate allergic reactions following coronavirus disease 2019 (COVID-19) vaccines and addresses revaccinating individuals with first-dose allergic reactions and allergy testing to determine revaccination outcomes. Recent meta-analyses assessed the incidence of severe allergic reactions to initial COVID-19 vaccination, risk of mRNA-COVID-19 revaccination after an initial reaction, and diagnostic accuracy of COVID-19 vaccine and vaccine excipient testing in predicting reactions. GRADE methods informed rating the certainty of evidence and strength of recommendations. A modified Delphi panel consisting of experts in allergy, anaphylaxis, vaccinology, infectious diseases, emergency medicine, and primary care from Australia, Canada, Europe, Japan, South Africa, the United Kingdom, and the United States formed the recommendations. We recommend vaccination for persons without COVID-19 vaccine excipient allergy and revaccination after a prior immediate allergic reaction. We suggest against >15-minute postvaccination observation. We recommend against mRNA vaccine or excipient skin testing to predict outcomes. We suggest revaccination of persons with an immediate allergic reaction to the mRNA vaccine or excipients be performed by a person with vaccine allergy expertise in a properly equipped setting. We suggest against premedication, split-dosing, or special precautions because of a comorbid allergic history.
- Published
- 2023